ImaginAb's Prostate Imaging Phase I/IIa data will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, alongside pre-clinical CD3+ T-cell imaging data
LOS ANGELES, June 5, 2015 /PRNewswire/ -- Memorial Sloan-Kettering Cancer Center (MKSCC), will be presenting ImaginAb's Phase I/IIa clinical imaging data with IAB2M in patients with metastatic prostate cancer. IAB2M is an anti-PSMA recombinant antibody fragment (a "minibody") derived from the huJ591 monoclonal antibody.
89Zr-Df-IAB2M is ImaginAb's lead product candidate under development as a diagnostic imaging agent for use with positron emission tomography/computed tomography (PET/CT) for detection of soft tissue and bone lesions in men with high risk prostate cancer. IAB2M is a reengineered monoclonal antibody fragment targeting prostate-specific membrane antigen (PSMA). PSMA is a highly promising target in prostate cancer, both because of its ubiquitous expression and its potential as a pharmacodynamic marker of androgen depletion.
"IAB2M has shown impressive sensitivity in Phase I/IIa imaging trials – it has the potential to impact patient care by accurately assessing the extent of disease in high-risk patient populations," said Jennifer Keppler, COO and President of ImaginAb, Inc. "Furthermore, ImaginAb's Zr-89 radiochemistry enables centralized manufacturing with the potential for rapid site recruitment during multicenter clinical trials and can also allow the rapid distribution to all PET imaging centers, without needing to be close to a cyclotron."
"Technologies to correctly diagnose and stage men with high-risk disease is a major unmet clinical need," commented Dr. Robert Reiter M.D., Urologist and Co-Founder of ImaginAb, Inc. "Molecular imaging strategies that target biologically relevant epitopes in prostate cancer have the potential to not only impact clinical care, but fundamentally change the way we clinically validate new drugs."
Data from ImaginAb's immune cell PET imaging programs will also be presented. This pre-clinical dataset validates antibody-based CD3+ T-cell imaging, and sets the stage for development of a CD3 targeted antibody fragment imaging agent. CD3 imaging will augment ImaginAb's ongoing CD8 imaging program, for use in evaluation of novel immune-oncology combination treatments, as well as engineered cell therapies.
About 89Zr-Df-IAB2M
89Zr-Df-IAB2M is a radiolabelled antibody fragment (a "minibody") under development as a diagnostic imaging agent for use with positron emission tomography/computed tomography (PET/CT) for detection of soft tissue and bone lesions in metastatic prostate cancer. 89Zr-Df-IAB2M targets prostate-specific membrane antigen (PSMA), a transmembrane protein highly expressed in the majority of prostate cancer, both localized and metastatic disease. PSMA has also been shown to be significantly overexpressed in response to androgen depletion, potentially enabling it to be used as a marker of response to anti-androgen therapy in patients with castrate-resistant disease. IAB2M is a hepatically-cleared imaging agent, meaning that there is no renal clearance and no bladder signal to obfuscate small lesions in the prostate bed. Ongoing clinical studies are evaluating the safety of 89Zr-Df-IAB2M tracer and determine its ability to accurately determine the extent of disease in several distinct prostate cancer patient populations with unmet clinical need. This immunoPET tracer has not yet been submitted for approval by the US Food and Drug Administration for clinical use.
About ImaginAb
ImaginAb, Inc. is redefining therapeutic management by harnessing the power of antibody technology for in vivo imaging. The company's proprietary antibody fragment platform yields actionable molecular information to guide treatment decisions in cancer and immunology. ImaginAb also collaborates with select biopharmaceutical partners to design imaging agents as companion diagnostics for therapeutic antibodies. ImaginAb's technology is positioned to deliver on the promise of precision medicine by improving patient outcomes and reducing the cost of healthcare. For more information, visit www.imaginab.com.
Logo - http://photos.prnewswire.com/prnh/20150605/221237LOGO
SOURCE ImaginAb, Inc.
Share this article